Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Terminated 5Recruiting 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Uterine Cervical Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Small Cell Lung Carcinoma 1Sarcoma 1Retinoblastoma 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Neuroblastoma 1Neoplasm Metastasis 1Lymphoma 1Lung Neoplasms 1Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Radiosurgery 10Temozolomide 6Magnetic Resonance Spectroscopy 6pembrolizumab 3Trastuzumab 3Radiation 3fluciclovine F-18 2cabazitaxel 2Surgical Procedures, Operative 2Specimen Handling 2Radiotherapy 2Magnetic Resonance Imaging 2Erlotinib Hydrochloride 2Carboplatin 2Bevacizumab 2Aminolevulinic Acid 2tucatinib 1thymoglobulin 1tepotinib 1temsirolimus 1sodium thiosulfate 1ribociclib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1neratinib 1lenvatinib 1irinotecan sucrosofate 1gancotamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Brain Neoplasms × Topotecan × Clear all
NCT01736800 2017-09-19

Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors

The Methodist Hospital Research Institute

Phase 2 Withdrawn
CNS

Brain Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡